|
|
Shares
|
Value
|
|
|
Common Stocks & Other Equity Interests-99.89%
|
|||
|
Capital Markets-72.18%
|
|||
|
ASX Ltd. (Australia)
|
|
17,696
|
$588,410
|
|
Cboe Global Markets, Inc.
|
|
7,844
|
2,616,445
|
|
CME Group, Inc., Class A
|
|
7,454
|
2,038,967
|
|
Coinbase Global, Inc., Class A(b)(c)
|
|
13,265
|
2,507,483
|
|
Deutsche Boerse AG (Germany)
|
|
7,704
|
2,220,662
|
|
Euronext N.V. (Netherlands)(d)
|
|
7,128
|
1,158,917
|
|
FactSet Research Systems, Inc.(c)
|
|
3,371
|
827,479
|
|
Hong Kong Exchanges & Clearing Ltd. (Hong
Kong)
|
|
45,015
|
2,298,318
|
|
HUB24 Ltd. (Australia)
|
|
7,199
|
429,321
|
|
Intercontinental Exchange, Inc.
|
|
13,955
|
2,063,247
|
|
Japan Exchange Group, Inc. (Japan)
|
|
94,066
|
1,149,676
|
|
London Stock Exchange Group PLC (United
Kingdom)
|
|
19,257
|
2,332,249
|
|
LPL Financial Holdings, Inc.
|
|
7,208
|
1,973,334
|
|
MarketAxess Holdings, Inc.(c)
|
|
3,280
|
426,531
|
|
Miami International Holdings, Inc.(b)
|
|
1,538
|
72,671
|
|
Moody’s Corp.
|
|
5,160
|
2,338,770
|
|
Morningstar, Inc.
|
|
2,075
|
377,691
|
|
MSCI, Inc.
|
|
4,175
|
2,636,011
|
|
Nasdaq, Inc.
|
|
26,248
|
2,428,465
|
|
S&P Global, Inc.
|
|
5,275
|
2,236,600
|
|
Singapore Exchange Ltd. (Singapore)
|
|
97,681
|
1,675,792
|
|
Tel Aviv Stock Exchange Ltd. (The) (Israel)
|
|
8,140
|
491,139
|
|
TMX Group Ltd. (Canada)
|
|
25,099
|
939,971
|
|
Tradeweb Markets, Inc., Class A
|
|
10,573
|
1,059,943
|
|
|
|
|
36,888,092
|
|
Professional Services-19.92%
|
|||
|
Broadridge Financial Solutions, Inc.
|
|
10,608
|
1,630,662
|
|
Equifax, Inc.
|
|
11,066
|
1,834,632
|
|
Experian PLC (Ireland)
|
|
66,270
|
2,290,677
|
|
|
Shares
|
Value
|
|
|
Professional Services-(continued)
|
|||
|
Thomson Reuters Corp. (Canada)(c)
|
|
11,711
|
$1,016,248
|
|
TransUnion
|
|
17,621
|
1,260,959
|
|
Verisk Analytics, Inc.
|
|
12,289
|
2,150,452
|
|
|
|
|
10,183,630
|
|
Software-7.79%
|
|||
|
Fair Isaac Corp.(b)
|
|
2,087
|
2,609,981
|
|
IRESS Ltd. (Australia)
|
|
16,242
|
70,351
|
|
SS&C Technologies Holdings, Inc.
|
|
19,265
|
1,300,773
|
|
|
|
|
3,981,105
|
|
TOTAL INVESTMENTS IN SECURITIES
(excluding investments purchased with cash collateral from
securities on loan)-99.89%
(Cost $50,820,933)
|
51,052,827
|
||
|
Investments Purchased with Cash Collateral
from Securities on Loan
|
|||
|
Money Market Funds-9.23%
|
|||
|
Invesco Private Government Fund,
3.58%(e)(f)(g)
|
|
1,313,143
|
1,313,143
|
|
Invesco Private Prime Fund, 3.75%(e)(f)(g)
|
|
3,402,364
|
3,403,044
|
|
Total Investments Purchased with Cash Collateral from
Securities on Loan
(Cost $4,716,187)
|
4,716,187
|
||
|
TOTAL INVESTMENTS IN SECURITIES-109.12%
(Cost $55,537,120)
|
55,769,014
|
||
|
OTHER ASSETS LESS LIABILITIES-(9.12)%
|
(4,661,438
)
|
||
|
NET ASSETS-100.00%
|
$51,107,576
|
||
|
Notes to Schedule of Investments:
|
|
|
(a)
|
Industry and/or sector classifications used in this report are generally according
to the Global Industry Classification Standard, which was developed by and is
the exclusive property and a service mark of MSCI Inc. and Standard & Poor’s.
|
|
(b)
|
Non-income producing security.
|
|
(c)
|
All or a portion of this security was out on loan at May 31, 2026.
|
|
(d)
|
Security purchased or received in a transaction exempt from registration under the Securities Act of 1933, as amended (the “1933 Act”). The security may be
resold pursuant to an exemption from registration under the 1933 Act, typically to
qualified institutional buyers. The value of this security at May 31, 2026
represented 2.27% of the Fund’s Net Assets.
|
|
(e)
|
Affiliated holding. Affiliated holdings are investments in entities which are under
common ownership or control of Invesco Ltd. or are investments in entities in
which the Fund owns 5% or more of the outstanding voting securities. The table below shows the Fund’s transactions in, and earnings from, its investments in
affiliates for the nine months ended May 31, 2026.
|
|
|
Value
August 31, 2025
|
Purchases
at Cost
|
Proceeds
from Sales
|
Change in
Unrealized
Appreciation
(Depreciation)
|
Realized
Gain
(Loss)
|
Value
May 31, 2026
|
Dividend Income
|
|
Investments in Affiliated
Money Market Funds:
|
|
|
|
|
|
|
|
|
Invesco Government &
Agency Portfolio, Institutional
Class
|
$29,546
|
$17,891,471
|
$(17,921,017
)
|
$-
|
$-
|
$-
|
$23,859
|
|
|
Value
August 31, 2025
|
Purchases
at Cost
|
Proceeds
from Sales
|
Change in
Unrealized
Appreciation
(Depreciation)
|
Realized
Gain
(Loss)
|
Value
May 31, 2026
|
Dividend Income
|
|
Investments Purchased with
Cash Collateral from
Securities on Loan:
|
|
|
|
|
|
|
|
|
Invesco Private Government
Fund
|
$1,664,981
|
$15,394,763
|
$(15,746,601
)
|
$-
|
$-
|
$1,313,143
|
$30,028
*
|
|
Invesco Private Prime Fund
|
4,333,803
|
38,769,869
|
(39,700,224
)
|
(89
)
|
(315
)
|
3,403,044
|
81,427
*
|
|
Total
|
$6,028,330
|
$72,056,103
|
$(73,367,842
)
|
$(89
)
|
$(315
)
|
$4,716,187
|
$135,314
|
|
*
|
Represents the income earned on the investment of cash collateral. Does not include
rebates and fees paid to lending agent or premiums received from
borrowers, if any.
|
|
(f)
|
The rate shown is the 7-day SEC standardized yield as of May 31, 2026.
|
|
(g)
|
The security has been segregated to satisfy the commitment to return the cash collateral received in securities lending transactions upon the borrower’s return
of the securities loaned.
|
|
|
Shares
|
Value
|
|
|
Common Stocks & Other Equity Interests-99.87%
|
|||
|
Biotechnology-81.50%
|
|||
|
4D Molecular Therapeutics, Inc.(b)(c)
|
|
2,688
|
$26,638
|
|
Abivax S.A., ADR (France)(b)
|
|
3,294
|
436,883
|
|
Absci Corp.(b)(c)
|
|
8,106
|
54,716
|
|
AC Immune S.A. (Switzerland)(b)(c)
|
|
5,312
|
14,130
|
|
Acadia Pharmaceuticals, Inc.(b)
|
|
9,144
|
198,059
|
|
ADMA Biologics, Inc.(b)(c)
|
|
12,768
|
101,889
|
|
Agios Pharmaceuticals, Inc.(b)(c)
|
|
3,120
|
91,728
|
|
Alkermes PLC(b)(c)
|
|
8,934
|
376,925
|
|
Allogene Therapeutics, Inc.(b)
|
|
11,864
|
25,745
|
|
Alnylam Pharmaceuticals, Inc.(b)
|
|
7,110
|
2,147,078
|
|
Altimmune, Inc.(b)(c)
|
|
6,611
|
20,164
|
|
Alvotech S.A. (Luxembourg)(b)(c)
|
|
17,707
|
59,496
|
|
Amgen, Inc.
|
|
14,213
|
4,786,796
|
|
AnaptysBio, Inc.(b)
|
|
1,484
|
82,614
|
|
Anavex Life Sciences Corp.(b)
|
|
4,878
|
14,780
|
|
Annexon, Inc.(b)(c)
|
|
7,808
|
42,319
|
|
Apogee Therapeutics, Inc.(b)(c)
|
|
2,933
|
240,917
|
|
Arbutus Biopharma Corp.(b)
|
|
10,311
|
47,018
|
|
Arcturus Therapeutics Holdings, Inc.(b)(c)
|
|
1,489
|
11,793
|
|
Arcutis Biotherapeutics, Inc.(b)(c)
|
|
6,650
|
142,709
|
|
Ardelyx, Inc.(b)(c)
|
|
13,224
|
79,873
|
|
argenx SE, ADR (Netherlands)(b)
|
|
1,521
|
1,271,541
|
|
ArriVent Biopharma, Inc.(b)(c)
|
|
2,201
|
66,624
|
|
Arrowhead Pharmaceuticals, Inc.(b)
|
|
7,507
|
584,870
|
|
ARS Pharmaceuticals, Inc.(b)(c)
|
|
5,331
|
48,352
|
|
Ascendis Pharma A/S (Denmark)(b)
|
|
3,301
|
739,787
|
|
Aura Biosciences, Inc.(b)(c)
|
|
3,345
|
24,987
|
|
Aurinia Pharmaceuticals, Inc. (Canada)(b)
|
|
7,129
|
109,288
|
|
Autolus Therapeutics PLC, ADR (United
Kingdom)(b)(c)
|
|
10,575
|
19,775
|
|
Beam Therapeutics, Inc.(b)(c)
|
|
5,461
|
179,831
|
|
BeOne Medicines Ltd., ADR(b)
|
|
1,714
|
493,495
|
|
Bicara Therapeutics, Inc.(b)(c)
|
|
3,380
|
73,515
|
|
Bicycle Therapeutics PLC, ADR (United
Kingdom)(b)(c)
|
|
2,439
|
11,439
|
|
BioCryst Pharmaceuticals, Inc.(b)(c)
|
|
13,446
|
119,804
|
|
Biogen, Inc.(b)
|
|
7,868
|
1,542,128
|
|
BioMarin Pharmaceutical, Inc.(b)
|
|
10,311
|
590,717
|
|
BioNTech SE, ADR (Germany)(b)
|
|
6,112
|
586,446
|
|
Black Diamond Therapeutics, Inc.(b)
|
|
3,013
|
6,689
|
|
BridgeBio Pharma, Inc.(b)
|
|
10,393
|
688,640
|
|
C4 Therapeutics, Inc.(b)
|
|
5,140
|
22,462
|
|
Cabaletta Bio, Inc.(b)(c)
|
|
5,083
|
19,214
|
|
Candel Therapeutics, Inc.(b)
|
|
3,866
|
32,088
|
|
Caribou Biosciences, Inc.(b)
|
|
4,925
|
11,623
|
|
Caris Life Sciences, Inc.(b)(c)
|
|
15,091
|
252,322
|
|
Cartesian Therapeutics, Inc., Rts., expiring
12/31/2049(b)(d)
|
|
2,633
|
359
|
|
Centessa Pharmaceuticals PLC, ADR(b)
|
|
6,401
|
254,504
|
|
CG Oncology, Inc.(b)(c)
|
|
4,527
|
281,987
|
|
Cogent Biosciences, Inc.(b)
|
|
8,702
|
304,222
|
|
Coherus Oncology, Inc.(b)
|
|
7,880
|
12,529
|
|
Compass Pathways PLC, ADR (United
Kingdom)(b)
|
|
5,056
|
66,031
|
|
Corvus Pharmaceuticals, Inc.(b)(c)
|
|
4,427
|
54,939
|
|
Crinetics Pharmaceuticals, Inc.(b)(c)
|
|
5,613
|
199,542
|
|
CRISPR Therapeutics AG (Switzerland)(b)
|
|
5,136
|
288,540
|
|
Cullinan Therapeutics, Inc.(b)(c)
|
|
3,167
|
52,065
|
|
Cytokinetics, Inc.(b)(c)
|
|
6,597
|
506,386
|
|
CytomX Therapeutics, Inc.(b)
|
|
8,930
|
32,148
|
|
Denali Therapeutics, Inc.(b)(c)
|
|
8,502
|
178,882
|
|
|
Shares
|
Value
|
|
|
Biotechnology-(continued)
|
|||
|
Design Therapeutics, Inc.(b)(c)
|
|
3,012
|
$31,566
|
|
Disc Medicine, Inc.(b)(c)
|
|
2,046
|
142,340
|
|
Dyne Therapeutics, Inc.(b)(c)
|
|
8,827
|
170,626
|
|
Editas Medicine, Inc.(b)(c)
|
|
5,143
|
17,795
|
|
Enanta Pharmaceuticals, Inc.(b)(c)
|
|
1,525
|
20,069
|
|
Entrada Therapeutics, Inc.(b)(c)
|
|
2,017
|
14,260
|
|
Erasca, Inc.(b)(c)
|
|
16,597
|
213,105
|
|
Exelixis, Inc.(b)
|
|
13,923
|
702,833
|
|
First Tracks Biotherapeutics, Inc.(b)(c)
|
|
1,472
|
23,493
|
|
Foghorn Therapeutics, Inc.(b)(c)
|
|
3,081
|
13,187
|
|
Galapagos N.V., ADR (Belgium)(b)
|
|
794
|
22,510
|
|
Genmab A/S, ADR (Denmark)(b)(c)
|
|
3,433
|
90,391
|
|
Geron Corp.(b)
|
|
34,223
|
42,779
|
|
Gilead Sciences, Inc.
|
|
37,039
|
4,979,153
|
|
Gossamer Bio., Inc.(b)(c)
|
|
12,208
|
2,819
|
|
GRAIL, Inc.(b)(c)
|
|
2,094
|
150,098
|
|
Grifols S.A., ADR (Spain)
|
|
6,540
|
51,339
|
|
Halozyme Therapeutics, Inc.(b)
|
|
6,327
|
420,999
|
|
Humacyte, Inc.(b)(c)
|
|
10,180
|
13,234
|
|
Ideaya Biosciences, Inc.(b)(c)
|
|
4,708
|
138,745
|
|
Immuneering Corp., Class A(b)(c)
|
|
3,407
|
19,658
|
|
ImmunityBio, Inc.(b)(c)
|
|
55,119
|
414,495
|
|
Immunocore Holdings PLC, ADR (United
Kingdom)(b)(c)
|
|
2,351
|
67,920
|
|
Immunovant, Inc.(b)(c)
|
|
10,912
|
363,370
|
|
Incyte Corp.(b)
|
|
10,669
|
1,032,119
|
|
Inhibrx Biosciences, Inc.(b)(c)
|
|
777
|
80,816
|
|
Insmed, Inc.(b)
|
|
11,556
|
1,235,452
|
|
Intellia Therapeutics, Inc.(b)(c)
|
|
6,285
|
88,430
|
|
Invivyd, Inc.(b)
|
|
14,607
|
16,652
|
|
Ionis Pharmaceuticals, Inc.(b)
|
|
8,856
|
677,484
|
|
Iovance Biotherapeutics, Inc.(b)(c)
|
|
22,004
|
90,216
|
|
Ironwood Pharmaceuticals, Inc.(b)
|
|
8,601
|
30,706
|
|
Janux Therapeutics, Inc.(b)(c)
|
|
3,213
|
46,878
|
|
Jyong Biotech Ltd. (Taiwan)(b)
|
|
3,924
|
8,633
|
|
KalVista Pharmaceuticals, Inc.(b)
|
|
2,736
|
73,516
|
|
Kamada Ltd. (Israel)(b)
|
|
3,054
|
23,852
|
|
Keros Therapeutics, Inc.(b)
|
|
1,610
|
18,113
|
|
Kiniksa Pharmaceuticals International PLC(b)
|
|
2,461
|
119,063
|
|
Kodiak Sciences, Inc.(b)(c)
|
|
3,273
|
120,152
|
|
Krystal Biotech, Inc.(b)(c)
|
|
1,567
|
484,250
|
|
Kura Oncology, Inc.(b)
|
|
4,597
|
46,889
|
|
Kymera Therapeutics, Inc.(b)(c)
|
|
4,377
|
356,375
|
|
Kyverna Therapeutics, Inc.(b)
|
|
3,022
|
25,747
|
|
Larimar Therapeutics, Inc.(b)
|
|
5,736
|
19,961
|
|
Legend Biotech Corp., ADR(b)(c)
|
|
4,525
|
122,899
|
|
LENZ Therapeutics, Inc.(b)(c)
|
|
1,658
|
12,899
|
|
Lexeo Therapeutics, Inc.(b)(c)
|
|
3,850
|
19,789
|
|
Lyell Immunopharma, Inc.(b)
|
|
1,119
|
19,392
|
|
Madrigal Pharmaceuticals, Inc.(b)(c)
|
|
1,230
|
611,642
|
|
MannKind Corp.(b)
|
|
16,518
|
62,273
|
|
MeiraGTx Holdings PLC(b)(c)
|
|
4,315
|
45,955
|
|
Mesoblast Ltd., ADR (Australia)(b)(c)
|
|
2,767
|
42,612
|
|
Mineralys Therapeutics, Inc.(b)(c)
|
|
4,243
|
133,655
|
|
Mirum Pharmaceuticals, Inc.(b)
|
|
3,235
|
328,352
|
|
Moderna, Inc.(b)
|
|
21,173
|
999,154
|
|
Monte Rosa Therapeutics, Inc.(b)(c)
|
|
4,064
|
80,101
|
|
Neurocrine Biosciences, Inc.(b)
|
|
5,381
|
851,812
|
|
Neurogene, Inc.(b)(c)
|
|
839
|
23,777
|
|
NewAmsterdam Pharma Co. N.V.
(Netherlands)(b)
|
|
6,171
|
207,839
|
|
NovaBridge Biosciences, ADR (China)(b)
|
|
5,925
|
10,902
|
|
|
Shares
|
Value
|
|
|
Biotechnology-(continued)
|
|||
|
Novavax, Inc.(b)(c)
|
|
8,735
|
$95,823
|
|
Nurix Therapeutics, Inc.(b)(c)
|
|
5,485
|
97,414
|
|
Nuvalent, Inc., Class A(b)(c)
|
|
3,923
|
433,060
|
|
Olema Pharmaceuticals, Inc.(b)(c)
|
|
4,281
|
56,466
|
|
ORIC Pharmaceuticals, Inc.(b)(c)
|
|
5,304
|
44,819
|
|
Oruka Therapeutics, Inc.(b)(c)
|
|
2,595
|
151,885
|
|
PepGen, Inc.(b)
|
|
3,627
|
5,441
|
|
Praxis Precision Medicines, Inc.(b)
|
|
1,493
|
522,505
|
|
Precigen, Inc.(b)(c)
|
|
18,903
|
82,039
|
|
Prime Medicine, Inc.(b)(c)
|
|
9,524
|
33,810
|
|
Protagonist Therapeutics, Inc.(b)
|
|
3,421
|
340,595
|
|
Prothena Corp. PLC (Ireland)(b)
|
|
2,828
|
28,789
|
|
PTC Therapeutics, Inc.(b)
|
|
4,433
|
327,377
|
|
Puma Biotechnology, Inc.(b)(c)
|
|
2,680
|
19,216
|
|
Pyxis Oncology, Inc.(b)(c)
|
|
3,278
|
5,900
|
|
Recursion Pharmaceuticals, Inc., Class A(b)(c)
|
|
27,806
|
99,824
|
|
Regeneron Pharmaceuticals, Inc.
|
|
5,570
|
3,424,325
|
|
REGENXBIO, Inc.(b)(c)
|
|
2,665
|
18,682
|
|
Relay Therapeutics, Inc.(b)(c)
|
|
9,582
|
134,627
|
|
Replimune Group, Inc.(b)(c)
|
|
4,362
|
37,906
|
|
Revolution Medicines, Inc.(b)
|
|
10,624
|
1,673,068
|
|
Rhythm Pharmaceuticals, Inc.(b)
|
|
3,661
|
323,340
|
|
Rigel Pharmaceuticals, Inc.(b)(c)
|
|
963
|
29,362
|
|
Rocket Pharmaceuticals, Inc.(b)(c)
|
|
5,735
|
17,606
|
|
Roivant Sciences Ltd.(b)
|
|
38,370
|
1,150,716
|
|
Sagimet Biosciences, Inc., Class A(b)
|
|
1,641
|
11,963
|
|
Sana Biotechnology, Inc.(b)(c)
|
|
14,370
|
47,421
|
|
Sarepta Therapeutics, Inc.(b)(c)
|
|
5,587
|
99,840
|
|
Savara, Inc.(b)(c)
|
|
10,908
|
56,722
|
|
Scholar Rock Holding Corp.(b)(c)
|
|
5,458
|
269,079
|
|
Silence Therapeutics PLC, ADR (United
Kingdom)(b)(c)
|
|
2,476
|
17,084
|
|
Sionna Therapeutics, Inc.(b)
|
|
2,393
|
102,468
|
|
Solid Biosciences, Inc.(b)(c)
|
|
4,114
|
30,197
|
|
Spyre Therapeutics, Inc.(b)(c)
|
|
4,207
|
309,215
|
|
Stoke Therapeutics, Inc.(b)(c)
|
|
3,080
|
95,203
|
|
Summit Therapeutics, Inc.(b)(c)
|
|
41,569
|
729,120
|
|
Syndax Pharmaceuticals, Inc.(b)(c)
|
|
4,729
|
92,641
|
|
Tango Therapeutics, Inc.(b)(c)
|
|
7,220
|
158,696
|
|
Taysha Gene Therapies, Inc.(b)(c)
|
|
14,607
|
85,743
|
|
Tectonic Therapeutic, Inc.(b)(c)
|
|
1,000
|
31,165
|
|
Tenaya Therapeutics, Inc.(b)
|
|
11,421
|
9,925
|
|
Travere Therapeutics, Inc.(b)
|
|
4,947
|
233,399
|
|
Twist Bioscience Corp.(b)(c)
|
|
3,287
|
219,802
|
|
Tyra Biosciences, Inc.(b)(c)
|
|
2,861
|
95,586
|
|
Ultragenyx Pharmaceutical, Inc.(b)
|
|
5,180
|
124,009
|
|
uniQure N.V. (Netherlands)(b)
|
|
3,340
|
95,290
|
|
United Therapeutics Corp.(b)
|
|
2,350
|
1,308,527
|
|
Upstream Bio, Inc.(b)(c)
|
|
2,840
|
23,742
|
|
UroGen Pharma Ltd.(b)(c)
|
|
2,509
|
70,578
|
|
Vanda Pharmaceuticals, Inc.(b)(c)
|
|
3,112
|
20,072
|
|
Vaxcyte, Inc.(b)(c)
|
|
7,716
|
396,602
|
|
Vera Therapeutics, Inc.(b)(c)
|
|
3,825
|
135,864
|
|
Veracyte, Inc.(b)(c)
|
|
4,260
|
197,408
|
|
Vericel Corp.(b)(c)
|
|
2,703
|
90,091
|
|
Vertex Pharmaceuticals, Inc.(b)
|
|
11,104
|
4,969,484
|
|
Vir Biotechnology, Inc.(b)(c)
|
|
8,374
|
79,888
|
|
Vor BioPharma, Inc.(b)
|
|
2,243
|
33,578
|
|
Voyager Therapeutics, Inc.(b)
|
|
3,102
|
12,005
|
|
Xencor, Inc.(b)(c)
|
|
3,932
|
46,712
|
|
Xenon Pharmaceuticals, Inc. (Canada)(b)
|
|
4,455
|
243,822
|
|
Zai Lab Ltd., ADR (China)(b)(c)
|
|
1,809
|
32,001
|
|
|
Shares
|
Value
|
|
|
Biotechnology-(continued)
|
|||
|
Zenas Biopharma, Inc.(b)(c)
|
|
2,878
|
$52,955
|
|
Zymeworks, Inc.(b)(c)
|
|
3,989
|
100,244
|
|
|
|
|
54,907,918
|
|
Health Care Equipment & Supplies-0.17%
|
|||
|
Novocure Ltd.(b)(c)
|
|
6,072
|
103,467
|
|
Orchestra Biomed Holdings, Inc.(b)
|
|
2,983
|
11,663
|
|
|
|
|
115,130
|
|
Health Care Providers & Services-1.40%
|
|||
|
Castle Biosciences, Inc.(b)
|
|
1,566
|
33,011
|
|
Guardant Health, Inc.(b)
|
|
7,032
|
911,980
|
|
|
|
|
944,991
|
|
Life Sciences Tools & Services-4.69%
|
|||
|
10X Genomics, Inc., Class A(b)
|
|
6,309
|
178,576
|
|
AbCellera Biologics, Inc. (Canada)(b)(c)
|
|
16,253
|
100,281
|
|
Adaptive Biotechnologies Corp.(b)
|
|
8,255
|
125,063
|
|
Alpha Teknova, Inc.(b)(c)
|
|
2,824
|
15,250
|
|
Codexis, Inc.(b)
|
|
4,766
|
13,202
|
|
Fortrea Holdings, Inc.(b)
|
|
5,013
|
77,150
|
|
Illumina, Inc.(b)
|
|
8,197
|
1,335,783
|
|
Lifecore Biomedical, Inc.(b)(c)
|
|
1,969
|
9,884
|
|
Maravai LifeSciences Holdings, Inc., Class A(b)
|
|
7,725
|
37,080
|
|
Medpace Holdings, Inc.(b)
|
|
1,522
|
680,501
|
|
OmniAb, Inc.(b)
|
|
7,582
|
20,471
|
|
OmniAb, Inc., Rts., expiring
11/02/2027(b)(c)(d)
|
|
125
|
0
|
|
OmniAb, Inc., Rts., expiring 11/02/2027(b)(d)
|
|
125
|
0
|
|
Pacific Biosciences of California, Inc.(b)(c)
|
|
15,934
|
23,742
|
|
Personalis, Inc.(b)(c)
|
|
5,529
|
63,031
|
|
Quantum-Si, Inc.(b)(c)
|
|
10,304
|
12,262
|
|
Tempus AI, Inc.(b)(c)
|
|
9,314
|
470,078
|
|
|
|
|
3,162,354
|
|
Pharmaceuticals-12.11%
|
|||
|
Aardvark Therapeutics, Inc.(b)
|
|
1,150
|
4,727
|
|
Aclaris Therapeutics, Inc.(b)
|
|
6,364
|
28,956
|
|
Alumis, Inc.(b)(c)
|
|
6,778
|
146,405
|
|
Amneal Pharmaceuticals, Inc.(b)
|
|
16,863
|
222,086
|
|
Amphastar Pharmaceuticals, Inc.(b)(c)
|
|
2,430
|
45,805
|
|
Amylyx Pharmaceuticals, Inc.(b)(c)
|
|
5,907
|
84,765
|
|
ANI Pharmaceuticals, Inc.(b)(c)
|
|
1,202
|
94,369
|
|
Aquestive Therapeutics, Inc.(b)(c)
|
|
6,441
|
25,893
|
|
Arvinas, Inc.(b)
|
|
3,371
|
30,272
|
|
AtaiBeckley, Inc.(b)(c)
|
|
19,357
|
87,687
|
|
Atea Pharmaceuticals, Inc.(b)(c)
|
|
4,127
|
19,273
|
|
Axsome Therapeutics, Inc.(b)
|
|
2,742
|
642,944
|
|
BioAge Labs, Inc.(b)(c)
|
|
2,294
|
39,663
|
|
Collegium Pharmaceutical, Inc.(b)(c)
|
|
1,685
|
56,633
|
|
Contineum Therapeutics, Inc., Class A(b)
|
|
1,608
|
21,692
|
|
CorMedix, Inc.(b)(c)
|
|
4,165
|
35,153
|
|
Definium Therapeutics, Inc.(b)(c)
|
|
5,345
|
129,296
|
|
Edgewise Therapeutics, Inc.(b)(c)
|
|
5,751
|
196,454
|
|
Enliven Therapeutics, Inc.(b)(c)
|
|
3,182
|
125,912
|
|
Esperion Therapeutics, Inc.(b)(c)
|
|
12,603
|
39,447
|
|
Eton Pharmaceuticals, Inc.(b)(c)
|
|
1,421
|
43,269
|
|
Evolus, Inc.(b)(c)
|
|
3,422
|
22,448
|
|
EyePoint, Inc.(b)(c)
|
|
4,438
|
60,268
|
|
Fulcrum Therapeutics, Inc.(b)(c)
|
|
3,501
|
24,227
|
|
GH Research PLC (Ireland)(b)(c)
|
|
3,325
|
79,767
|
|
Harmony Biosciences Holdings, Inc.(b)(c)
|
|
3,083
|
97,392
|
|
Harrow, Inc.(b)(c)
|
|
1,970
|
69,364
|
|
Indivior Pharmaceuticals, Inc.(b)
|
|
6,697
|
241,226
|
|
|
Shares
|
Value
|
|
|
Pharmaceuticals-(continued)
|
|||
|
Innoviva, Inc.(b)
|
|
3,971
|
$85,059
|
|
Jazz Pharmaceuticals PLC(b)
|
|
3,300
|
780,417
|
|
Ligand Pharmaceuticals, Inc.(b)
|
|
1,069
|
247,965
|
|
Maze Therapeutics, Inc.(b)(c)
|
|
2,580
|
68,267
|
|
MBX Biosciences, Inc.(b)(c)
|
|
2,407
|
75,748
|
|
Neumora Therapeutics, Inc.(b)
|
|
8,812
|
16,302
|
|
Novo Nordisk A/S (Denmark)(b)(d)
|
|
3,794
|
0
|
|
Ocular Therapeutix, Inc.(b)(c)
|
|
11,671
|
105,156
|
|
Omeros Corp.(b)(c)
|
|
3,801
|
41,963
|
|
Pacira BioSciences, Inc.(b)
|
|
2,147
|
49,853
|
|
Pharvaris N.V. (Netherlands)(b)
|
|
3,443
|
103,841
|
|
Phathom Pharmaceuticals, Inc.(b)(c)
|
|
4,246
|
40,719
|
|
Phibro Animal Health Corp., Class A
|
|
1,102
|
33,931
|
|
Rani Therapeutics Holdings, Inc., Class A(b)
|
|
5,139
|
4,886
|
|
Rapport Therapeutics, Inc.(b)(c)
|
|
2,574
|
101,673
|
|
Royalty Pharma PLC, Class A
|
|
22,968
|
1,280,696
|
|
Sanofi S.A., ADR
|
|
13,122
|
573,038
|
|
Septerna, Inc.(b)(c)
|
|
2,373
|
71,665
|
|
SIGA Technologies, Inc.(c)
|
|
3,769
|
17,639
|
|
Structure Therapeutics, Inc., ADR(b)(c)
|
|
4,176
|
164,284
|
|
Supernus Pharmaceuticals, Inc.(b)
|
|
3,074
|
141,957
|
|
Tarsus Pharmaceuticals, Inc.(b)(c)
|
|
2,282
|
135,551
|
|
Theravance Biopharma, Inc.(b)(c)
|
|
2,717
|
43,635
|
|
Third Harmonic Bio, Inc., Class B(b)(d)
|
|
1,605
|
0
|
|
Trevi Therapeutics, Inc.(b)(c)
|
|
6,830
|
96,576
|
|
Viatris, Inc.
|
|
61,728
|
1,003,697
|
|
WaVe Life Sciences Ltd.(b)(c)
|
|
10,093
|
66,412
|
|
Xeris Biopharma Holdings, Inc.(b)(c)
|
|
8,895
|
54,793
|
|
Zevra Therapeutics, Inc.(b)(c)
|
|
2,973
|
34,457
|
|
|
|
|
8,155,573
|
|
Total Common Stocks & Other Equity Interests
(Cost $62,133,032)
|
67,285,966
|
||
|
|
Shares
|
Value
|
|
|
|
|||
|
Money Market Funds-0.01%
|
|
|
|
|
Invesco Government & Agency Portfolio,
Institutional Class, 3.53%(e)(f)
(Cost $5,398)
|
|
5,398
|
$5,398
|
|
TOTAL INVESTMENTS IN SECURITIES
(excluding investments purchased with cash collateral
from securities on loan)-99.88%
(Cost $62,138,430)
|
67,291,364
|
||
|
Investments Purchased with Cash Collateral
from Securities on Loan
|
|||
|
Money Market Funds-19.68%
|
|||
|
Invesco Private Government Fund,
3.58%(e)(f)(g)
|
|
3,691,132
|
3,691,132
|
|
Invesco Private Prime Fund, 3.75%(e)(f)(g)
|
|
9,567,964
|
9,569,878
|
|
Total Investments Purchased with Cash Collateral from
Securities on Loan
(Cost $13,260,408)
|
13,261,010
|
||
|
TOTAL INVESTMENTS IN SECURITIES-119.56%
(Cost $75,398,838)
|
80,552,374
|
||
|
OTHER ASSETS LESS LIABILITIES-(19.56)%
|
(13,178,833
)
|
||
|
NET ASSETS-100.00%
|
$67,373,541
|
||
|
Investment Abbreviations:
|
|
|
ADR
|
-American Depositary Receipt
|
|
Rts.
|
-Rights
|
|
Notes to Schedule of Investments:
|
|
|
(a)
|
Industry and/or sector classifications used in this report are generally according
to the Global Industry Classification Standard, which was developed by and is
the exclusive property and a service mark of MSCI Inc. and Standard & Poor’s.
|
|
(b)
|
Non-income producing security.
|
|
(c)
|
All or a portion of this security was out on loan at May 31, 2026.
|
|
(d)
|
Security valued using significant unobservable inputs (Level 3). See Note 1.
|
|
(e)
|
Affiliated holding. Affiliated holdings are investments in entities which are under
common ownership or control of Invesco Ltd. or are investments in entities in
which the Fund owns 5% or more of the outstanding voting securities. The table below shows the Fund’s transactions in, and earnings from, its investments in
affiliates for the nine months ended May 31, 2026.
|
|
|
Value
August 31, 2025
|
Purchases
at Cost
|
Proceeds
from Sales
|
Change in
Unrealized
Appreciation
|
Realized
Gain
(Loss)
|
Value
May 31, 2026
|
Dividend Income
|
|
Investments in Affiliated
Money Market Funds:
|
|
|
|
|
|
|
|
|
Invesco Government & Agency
Portfolio, Institutional Class
|
$18,857
|
$557,855
|
$(571,314
)
|
$-
|
$-
|
$5,398
|
$1,036
|
|
|
Value
August 31, 2025
|
Purchases
at Cost
|
Proceeds
from Sales
|
Change in
Unrealized
Appreciation
|
Realized
Gain
(Loss)
|
Value
May 31, 2026
|
Dividend Income
|
|
Investments Purchased with
Cash Collateral from
Securities on Loan:
|
|
|
|
|
|
|
|
|
Invesco Private Government
Fund
|
$1,910,357
|
$14,971,062
|
$(13,190,287
)
|
$-
|
$-
|
$3,691,132
|
$94,460
*
|
|
Invesco Private Prime Fund
|
4,966,542
|
33,392,404
|
(28,788,145
)
|
299
|
(1,222
)
|
9,569,878
|
254,468
*
|
|
Total
|
$6,895,756
|
$48,921,321
|
$(42,549,746
)
|
$299
|
$(1,222
)
|
$13,266,408
|
$349,964
|
|
*
|
Represents the income earned on the investment of cash collateral. Does not include
rebates and fees paid to lending agent or premiums received from
borrowers, if any.
|
|
(f)
|
The rate shown is the 7-day SEC standardized yield as of May 31, 2026.
|
|
(g)
|
The security has been segregated to satisfy the commitment to return the cash collateral received in securities lending transactions upon the borrower’s return
of the securities loaned.
|
|
|
Shares
|
Value
|
|
|
Common Stocks & Other Equity Interests-100.02%
|
|||
|
Building Products-1.08%
|
|||
|
Owens Corning
|
|
1,012
|
$127,330
|
|
Commercial Services & Supplies-6.20%
|
|||
|
Cintas Corp.
|
|
1,324
|
226,748
|
|
Clean Harbors, Inc.(b)
|
|
499
|
140,234
|
|
Republic Services, Inc.
|
|
1,111
|
222,689
|
|
Rollins, Inc.
|
|
3,027
|
144,085
|
|
|
|
|
733,756
|
|
Electronic Equipment, Instruments & Components-1.46%
|
|||
|
Teledyne Technologies, Inc.(b)
|
|
279
|
172,932
|
|
Entertainment-2.05%
|
|||
|
Warner Bros. Discovery, Inc.(b)
|
|
8,984
|
242,658
|
|
Financial Services-4.06%
|
|||
|
Mastercard, Inc., Class A
|
|
972
|
480,148
|
|
Food Products-0.54%
|
|||
|
Marzetti Co. (The)
|
|
567
|
63,470
|
|
Ground Transportation-1.98%
|
|||
|
Old Dominion Freight Line, Inc.
|
|
1,038
|
233,706
|
|
Health Care Equipment & Supplies-3.12%
|
|||
|
Becton, Dickinson and Co.
|
|
1,271
|
186,990
|
|
Dexcom, Inc.(b)
|
|
2,476
|
182,580
|
|
|
|
|
369,570
|
|
Health Care Providers & Services-1.66%
|
|||
|
Chemed Corp.
|
|
246
|
104,897
|
|
CorVel Corp.(b)(c)
|
|
1,486
|
91,760
|
|
|
|
|
196,657
|
|
Health Care Technology-1.50%
|
|||
|
Veeva Systems, Inc., Class A(b)
|
|
1,020
|
177,827
|
|
Hotels, Restaurants & Leisure-1.24%
|
|||
|
Domino’s Pizza, Inc.
|
|
346
|
107,461
|
|
Nathan’s Famous, Inc.(c)
|
|
386
|
38,947
|
|
|
|
|
146,408
|
|
Household Durables-1.14%
|
|||
|
NVR, Inc.(b)
|
|
22
|
134,306
|
|
Household Products-1.34%
|
|||
|
Church & Dwight Co., Inc.
|
|
1,655
|
158,268
|
|
Interactive Media & Services-6.26%
|
|||
|
Meta Platforms, Inc., Class A
|
|
1,170
|
740,037
|
|
IT Services-2.02%
|
|||
|
Everforth, Inc.(b)(c)
|
|
1,543
|
34,995
|
|
VeriSign, Inc.
|
|
715
|
204,047
|
|
|
|
|
239,042
|
|
Life Sciences Tools & Services-4.25%
|
|||
|
Mettler-Toledo International, Inc.(b)
|
|
132
|
155,837
|
|
Thermo Fisher Scientific, Inc.
|
|
705
|
347,219
|
|
|
|
|
503,056
|
|
Machinery-2.95%
|
|||
|
Proto Labs, Inc.(b)(c)
|
|
997
|
75,533
|
|
|
Shares
|
Value
|
|
|
Machinery-(continued)
|
|||
|
Watts Water Technologies, Inc., Class A
|
|
366
|
$113,087
|
|
Xylem, Inc.
|
|
1,460
|
159,928
|
|
|
|
|
348,548
|
|
Professional Services-6.70%
|
|||
|
Automatic Data Processing, Inc.
|
|
1,275
|
282,846
|
|
Exponent, Inc.
|
|
1,177
|
68,643
|
|
Leidos Holdings, Inc.
|
|
950
|
121,410
|
|
Paychex, Inc.
|
|
2,069
|
200,651
|
|
Paycom Software, Inc.
|
|
855
|
119,418
|
|
|
|
|
792,968
|
|
Semiconductors & Semiconductor Equipment-24.61%
|
|||
|
Broadcom, Inc.
|
|
2,432
|
1,086,545
|
|
KLA Corp.
|
|
244
|
468,897
|
|
NVIDIA Corp.
|
|
6,423
|
1,356,152
|
|
|
|
|
2,911,594
|
|
Software-25.86%
|
|||
|
Adobe, Inc.(b)
|
|
1,127
|
292,130
|
|
Cadence Design Systems, Inc.(b)
|
|
893
|
334,812
|
|
Fair Isaac Corp.(b)
|
|
137
|
171,331
|
|
Fortinet, Inc.(b)
|
|
3,000
|
413,910
|
|
Intuit, Inc.
|
|
738
|
244,669
|
|
Manhattan Associates, Inc.(b)
|
|
852
|
127,843
|
|
Progress Software Corp.(b)(c)
|
|
1,578
|
51,806
|
|
PTC, Inc.(b)
|
|
997
|
138,314
|
|
Qualys, Inc.(b)
|
|
898
|
98,142
|
|
ReposiTrak, Inc.
|
|
3,154
|
32,581
|
|
Roper Technologies, Inc.
|
|
569
|
185,227
|
|
Salesforce, Inc.
|
|
1,834
|
350,477
|
|
ServiceNow, Inc.(b)
|
|
2,793
|
347,365
|
|
SPS Commerce, Inc.(b)
|
|
1,249
|
70,881
|
|
Workday, Inc., Class A(b)
|
|
1,364
|
199,403
|
|
|
|
|
3,058,891
|
|
TOTAL INVESTMENTS IN SECURITIES
(excluding investments purchased with cash collateral from
securities on loan)-100.02%
(Cost $11,841,461)
|
11,831,172
|
||
|
Investments Purchased with Cash Collateral
from Securities on Loan
|
|||
|
Money Market Funds-1.60%
|
|||
|
Invesco Private Government Fund, 3.58%(d)(e)(f)
|
|
52,546
|
52,546
|
|
Invesco Private Prime Fund, 3.75%(d)(e)(f)
|
|
136,693
|
136,720
|
|
Total Investments Purchased with Cash Collateral from
Securities on Loan
(Cost $189,265)
|
189,266
|
||
|
TOTAL INVESTMENTS IN SECURITIES-101.62%
(Cost $12,030,726)
|
12,020,438
|
||
|
OTHER ASSETS LESS LIABILITIES-(1.62)%
|
(191,546
)
|
||
|
NET ASSETS-100.00%
|
$11,828,892
|
||
|
Notes to Schedule of Investments:
|
|
|
(a)
|
Industry and/or sector classifications used in this report are generally according
to the Global Industry Classification Standard, which was developed by and is
the exclusive property and a service mark of MSCI Inc. and Standard & Poor’s.
|
|
(b)
|
Non-income producing security.
|
|
(c)
|
All or a portion of this security was out on loan at May 31, 2026.
|
|
(d)
|
Affiliated holding. Affiliated holdings are investments in entities which are under
common ownership or control of Invesco Ltd. or are investments in entities in
which the Fund owns 5% or more of the outstanding voting securities. The table below shows the Fund’s transactions in, and earnings from, its investments in
affiliates for the nine months ended May 31, 2026.
|
|
|
Value
August 31, 2025
|
Purchases
at Cost
|
Proceeds
from Sales
|
Change in
Unrealized
Appreciation
(Depreciation)
|
Realized
Gain
|
Value
May 31, 2026
|
Dividend Income
|
|
Investments in Affiliated
Money Market Funds:
|
|
|
|
|
|
|
|
|
Invesco Government & Agency
Portfolio, Institutional Class
|
$1,107
|
$79,648
|
$(80,755
)
|
$-
|
$-
|
$-
|
$91
|
|
Investments Purchased with
Cash Collateral from Securities
on Loan:
|
|
|
|
|
|
|
|
|
Invesco Private Government
Fund
|
172,276
|
1,572,631
|
(1,692,361
)
|
-
|
-
|
52,546
|
1,494
*
|
|
Invesco Private Prime Fund
|
449,254
|
3,644,105
|
(3,956,611
)
|
(34
)
|
6
|
136,720
|
3,903
*
|
|
Total
|
$622,637
|
$5,296,384
|
$(5,729,727
)
|
$(34
)
|
$6
|
$189,266
|
$5,488
|
|
*
|
Represents the income earned on the investment of cash collateral. Does not include
rebates and fees paid to lending agent or premiums received from
borrowers, if any.
|
|
(e)
|
The rate shown is the 7-day SEC standardized yield as of May 31, 2026.
|
|
(f)
|
The security has been segregated to satisfy the commitment to return the cash collateral received in securities lending transactions upon the borrower’s return
of the securities loaned.
|
|
|
Shares
|
Value
|
|
|
Common Stocks & Other Equity Interests-99.95%
|
|||
|
Electronic Equipment, Instruments & Components-2.50%
|
|||
|
Coherent Corp.(b)
|
|
168,069
|
$60,751,902
|
|
Semiconductors & Semiconductor Equipment-97.45%
|
|||
|
Advanced Micro Devices, Inc.(b)
|
|
305,304
|
157,567,394
|
|
Analog Devices, Inc.
|
|
171,851
|
71,120,536
|
|
Applied Materials, Inc.
|
|
163,973
|
73,797,688
|
|
ARM Holdings PLC, ADR(b)(c)
|
|
125,054
|
44,180,328
|
|
ASML Holding N.V., New York Shares
(Netherlands)
|
|
42,119
|
67,927,838
|
|
Astera Labs, Inc.(b)
|
|
152,508
|
52,287,368
|
|
Broadcom, Inc.
|
|
477,923
|
213,521,659
|
|
Credo Technology Group Holding Ltd.(b)
|
|
154,974
|
36,578,513
|
|
Entegris, Inc.
|
|
136,045
|
18,881,685
|
|
GLOBALFOUNDRIES, Inc.(b)
|
|
497,800
|
39,809,066
|
|
Intel Corp.(b)
|
|
1,339,792
|
153,647,347
|
|
KLA Corp.
|
|
39,963
|
76,797,297
|
|
Lam Research Corp.
|
|
261,195
|
83,107,025
|
|
MACOM Technology Solutions Holdings,
Inc.(b)
|
|
67,220
|
24,511,101
|
|
Marvell Technology, Inc.
|
|
748,150
|
153,370,750
|
|
Microchip Technology, Inc.
|
|
484,584
|
45,865,876
|
|
Micron Technology, Inc.
|
|
296,230
|
287,639,330
|
|
Monolithic Power Systems, Inc.
|
|
44,209
|
69,240,578
|
|
Nova Ltd. (Israel)(b)
|
|
28,577
|
14,355,084
|
|
NVIDIA Corp.
|
|
1,034,612
|
218,447,978
|
|
NXP Semiconductors N.V. (Netherlands)
|
|
226,573
|
72,809,233
|
|
ON Semiconductor Corp.(b)
|
|
352,690
|
42,541,468
|
|
Qorvo, Inc.(b)
|
|
83,003
|
8,595,791
|
|
QUALCOMM, Inc.
|
|
429,333
|
107,771,170
|
|
Rambus, Inc.(b)
|
|
96,429
|
14,026,562
|
|
Skyworks Solutions, Inc.
|
|
134,663
|
10,483,514
|
|
Taiwan Semiconductor Manufacturing Co.
Ltd., ADR (Taiwan)
|
|
163,294
|
68,330,374
|
|
|
Shares
|
Value
|
|
|
Semiconductors & Semiconductor Equipment-(continued)
|
|||
|
Teradyne, Inc.
|
|
140,386
|
$52,547,884
|
|
Texas Instruments, Inc.
|
|
287,920
|
88,011,386
|
|
|
|
|
2,367,771,823
|
|
Total Common Stocks & Other Equity Interests
(Cost $1,559,951,781)
|
2,428,523,725
|
||
|
|
|||
|
Money Market Funds-0.04%
|
|
|
|
|
Invesco Government & Agency Portfolio,
Institutional Class, 3.53%(d)(e)
(Cost $979,209)
|
|
979,209
|
979,209
|
|
TOTAL INVESTMENTS IN SECURITIES
(excluding investments purchased with cash collateral
from securities on loan)-99.99%
(Cost $1,560,930,990)
|
2,429,502,934
|
||
|
Investments Purchased with Cash Collateral
from Securities on Loan
|
|||
|
Money Market Funds-0.89%
|
|||
|
Invesco Private Government Fund,
3.58%(d)(e)(f)
|
|
5,958,311
|
5,958,311
|
|
Invesco Private Prime Fund, 3.75%(d)(e)(f)
|
|
15,515,891
|
15,518,994
|
|
Total Investments Purchased with Cash Collateral from
Securities on Loan
(Cost $21,477,305)
|
21,477,305
|
||
|
TOTAL INVESTMENTS IN SECURITIES-100.88%
(Cost $1,582,408,295)
|
2,450,980,239
|
||
|
OTHER ASSETS LESS LIABILITIES-(0.88)%
|
(21,298,731
)
|
||
|
NET ASSETS-100.00%
|
$2,429,681,508
|
||
|
Investment Abbreviations:
|
|
|
ADR
|
-American Depositary Receipt
|
|
Notes to Schedule of Investments:
|
|
|
(a)
|
Industry and/or sector classifications used in this report are generally according
to the Global Industry Classification Standard, which was developed by and is
the exclusive property and a service mark of MSCI Inc. and Standard & Poor’s.
|
|
(b)
|
Non-income producing security.
|
|
(c)
|
All or a portion of this security was out on loan at May 31, 2026.
|
|
(d)
|
Affiliated holding. Affiliated holdings are investments in entities which are under
common ownership or control of Invesco Ltd. or are investments in entities in
which the Fund owns 5% or more of the outstanding voting securities. The table below shows the Fund’s transactions in, and earnings from, its investments in
affiliates for the nine months ended May 31, 2026.
|
|
|
Value
August 31, 2025
|
Purchases
at Cost
|
Proceeds
from Sales
|
Change in
Unrealized
Appreciation
|
Realized
Gain
(Loss)
|
Value
May 31, 2026
|
Dividend Income
|
|
Investments in Affiliated
Money Market Funds:
|
|
|
|
|
|
|
|
|
Invesco Government &
Agency Portfolio,
Institutional Class
|
$494,476
|
$7,718,470
|
$(7,233,737
)
|
$-
|
$-
|
$979,209
|
$16,054
|
|
|
Value
August 31, 2025
|
Purchases
at Cost
|
Proceeds
from Sales
|
Change in
Unrealized
Appreciation
|
Realized
Gain
(Loss)
|
Value
May 31, 2026
|
Dividend Income
|
|
Investments Purchased
with Cash Collateral from
Securities on Loan:
|
|
|
|
|
|
|
|
|
Invesco Private Government
Fund
|
$52,246
|
$158,686,579
|
$(152,780,514
)
|
$-
|
$-
|
$5,958,311
|
$129,711
*
|
|
Invesco Private Prime Fund
|
214,645
|
332,851,608
|
(317,542,491
)
|
-
|
(4,768
)
|
15,518,994
|
342,300
*
|
|
Total
|
$761,367
|
$499,256,657
|
$(477,556,742
)
|
$-
|
$(4,768
)
|
$22,456,514
|
$488,065
|
|
*
|
Represents the income earned on the investment of cash collateral. Does not include
rebates and fees paid to lending agent or premiums received from
borrowers, if any.
|
|
(e)
|
The rate shown is the 7-day SEC standardized yield as of May 31, 2026.
|
|
(f)
|
The security has been segregated to satisfy the commitment to return the cash collateral received in securities lending transactions upon the borrower’s return
of the securities loaned.
|
|
|
Shares
|
Value
|
|
|
Common Stocks & Other Equity Interests-100.03%
|
|||
|
Construction & Engineering-0.93%
|
|||
|
West Holdings Corp. (Japan)(b)
|
|
1,255,487
|
$21,248,707
|
|
Electrical Equipment-20.45%
|
|||
|
Array Technologies, Inc.(b)(c)
|
|
6,113,106
|
55,507,003
|
|
Nextpower, Inc., Class A(b)(c)
|
|
1,437,951
|
224,895,536
|
|
Shoals Technologies Group, Inc.,
Class A(b)(c)
|
|
6,232,364
|
77,592,932
|
|
Sunrun, Inc.(b)(c)
|
|
6,619,985
|
110,686,149
|
|
|
|
|
468,681,620
|
|
Financial Services-3.46%
|
|||
|
HA Sustainable Infrastructure Capital,
Inc.(b)
|
|
1,935,589
|
79,359,149
|
|
Independent Power and Renewable Electricity Producers-30.49%
|
|||
|
Clearway Energy, Inc., Class C
|
|
1,400,038
|
57,625,564
|
|
Doral Group Renewable Energy Resources
Ltd. (Israel)(b)(c)
|
|
3,162,142
|
116,605,004
|
|
Energix-Renewable Energies Ltd. (Israel)
|
|
5,993,592
|
61,701,828
|
|
Enlight Renewable Energy Ltd. (Israel)(c)
|
|
1,613,259
|
173,834,875
|
|
Grenergy Renovables S.A. (Spain)(c)
|
|
359,757
|
51,663,257
|
|
OY Nofar Energy Ltd. (Israel)(c)
|
|
965,611
|
96,635,529
|
|
ReNew Energy Global PLC, Class A
(India)(b)(c)
|
|
3,665,157
|
23,420,353
|
|
Scatec ASA (South Africa)(c)(d)
|
|
2,638,685
|
29,474,198
|
|
Solaria Energia y Medio Ambiente S.A.
(Spain)(c)
|
|
2,571,952
|
70,472,834
|
|
Xinyi Energy Holdings Ltd. (China)(b)
|
|
109,865,881
|
17,533,206
|
|
|
|
|
698,966,648
|
|
Semiconductors & Semiconductor Equipment-44.70%
|
|||
|
Canadian Solar, Inc. (Canada)(b)(c)
|
|
1,753,989
|
33,308,251
|
|
Daqo New Energy Corp., ADR (China)(b)(c)
|
|
1,932,235
|
32,152,390
|
|
Enphase Energy, Inc.(b)(c)
|
|
2,935,228
|
200,652,186
|
|
First Solar, Inc.(c)
|
|
877,438
|
269,189,204
|
|
Flat Glass Group Co. Ltd., H Shares
(China)(b)
|
|
20,396,136
|
21,634,983
|
|
GCL Technology Holdings Ltd.
(China)(b)(c)
|
|
647,666,939
|
68,660,844
|
|
Gigastorage Corp. (Taiwan)(c)
|
|
18,451,000
|
20,215,425
|
|
HD Hyundai Energy Solutions Co. Ltd.
(South Korea)(c)
|
|
237,453
|
27,604,490
|
|
|
Shares
|
Value
|
|
|
Semiconductors & Semiconductor Equipment-(continued)
|
|||
|
JinkoSolar Holding Co. Ltd., ADR
(China)(b)
|
|
1,266,065
|
$29,511,975
|
|
Motech Industries, Inc. (Taiwan)
|
|
21,866,000
|
20,937,237
|
|
SMA Solar Technology AG (Germany)(b)(c)
|
|
639,538
|
48,899,480
|
|
SolarEdge Technologies, Inc.(b)(c)
|
|
1,896,418
|
144,791,514
|
|
TSEC Corp. (Taiwan)(c)
|
|
20,849,000
|
26,911,360
|
|
United Renewable Energy Co. Ltd.
(Taiwan)(c)
|
|
54,737,458
|
31,915,638
|
|
Xinyi Solar Holdings Ltd. (China)(b)
|
|
141,117,927
|
48,128,930
|
|
|
|
|
1,024,513,907
|
|
Total Common Stocks & Other Equity Interests
(Cost $1,764,726,932)
|
2,292,770,031
|
||
|
|
|||
|
Money Market Funds-0.04%
|
|
|
|
|
Invesco Government & Agency Portfolio,
Institutional Class, 3.53%(e)(f)
(Cost $872,051)
|
|
872,051
|
872,051
|
|
TOTAL INVESTMENTS IN SECURITIES
(excluding investments purchased with cash collateral
from securities on loan)-100.07%
(Cost $1,765,598,983)
|
2,293,642,082
|
||
|
Investments Purchased with Cash Collateral
from Securities on Loan
|
|||
|
Money Market Funds-22.01%
|
|||
|
Invesco Private Government Fund,
3.58%(e)(f)(g)
|
|
138,562,898
|
138,562,898
|
|
Invesco Private Prime Fund, 3.75%(e)(f)(g)
|
|
365,892,092
|
365,965,270
|
|
Total Investments Purchased with Cash Collateral from
Securities on Loan
(Cost $504,513,773)
|
504,528,168
|
||
|
TOTAL INVESTMENTS IN SECURITIES-122.08%
(Cost $2,270,112,756)
|
2,798,170,250
|
||
|
OTHER ASSETS LESS LIABILITIES-(22.08)%
|
(506,002,828
)
|
||
|
NET ASSETS-100.00%
|
$2,292,167,422
|
||
|
Investment Abbreviations:
|
|
|
ADR
|
-American Depositary Receipt
|
|
Notes to Schedule of Investments:
|
|
|
(a)
|
Industry and/or sector classifications used in this report are generally according
to the Global Industry Classification Standard, which was developed by and is
the exclusive property and a service mark of MSCI Inc. and Standard & Poor’s.
|
|
(b)
|
All or a portion of this security was out on loan at May 31, 2026.
|
|
(c)
|
Non-income producing security.
|
|
(d)
|
Security purchased or received in a transaction exempt from registration under the Securities Act of 1933, as amended (the “1933 Act”). The security may be
resold pursuant to an exemption from registration under the 1933 Act, typically to
qualified institutional buyers. The value of this security at May 31, 2026
represented 1.29% of the Fund’s Net Assets.
|
|
(e)
|
Affiliated holding. Affiliated holdings are investments in entities which are under
common ownership or control of Invesco Ltd. or are investments in entities in
which the Fund owns 5% or more of the outstanding voting securities. The table below shows the Fund’s transactions in, and earnings from, its investments in
affiliates for the nine months ended May 31, 2026.
|
|
|
Value
August 31, 2025
|
Purchases
at Cost
|
Proceeds
from Sales
|
Change in
Unrealized
Appreciation
|
Realized
Gain
(Loss)
|
Value
May 31, 2026
|
Dividend Income
|
|
Investments in
Affiliated Money
Market Funds:
|
|
|
|
|
|
|
|
|
Invesco Government &
Agency Portfolio,
Institutional Class
|
$-
|
$108,581,551
|
$(107,709,500
)
|
$-
|
$-
|
$872,051
|
$40,906
|
|
Investments
Purchased with Cash
Collateral from
Securities on Loan:
|
|
|
|
|
|
|
|
|
Invesco Private
Government Fund
|
50,910,793
|
490,708,443
|
(403,056,338
)
|
-
|
-
|
138,562,898
|
1,809,037
*
|
|
Invesco Private Prime
Fund
|
132,364,120
|
1,058,626,202
|
(825,009,151
)
|
4,509
|
(20,410
)
|
365,965,270
|
4,896,591
*
|
|
Total
|
$183,274,913
|
$1,657,916,196
|
$(1,335,774,989
)
|
$4,509
|
$(20,410
)
|
$505,400,219
|
$6,746,534
|
|
*
|
Represents the income earned on the investment of cash collateral. Does not include
rebates and fees paid to lending agent or premiums received from
borrowers, if any.
|
|
(f)
|
The rate shown is the 7-day SEC standardized yield as of May 31, 2026.
|
|
(g)
|
The security has been segregated to satisfy the commitment to return the cash collateral received in securities lending transactions upon the borrower’s return
of the securities loaned.
|
|
This Fund has holdings greater than 10% of net assets in the following country:
|
|
|
Israel
|
19.58%
|
|
|
Level 1
|
Level 2
|
Level 3
|
Total
|
|
Invesco Bloomberg Financial Data Providers ETF
|
|
|
|
|
|
Investments in Securities
|
|
|
|
|
|
Common Stocks & Other Equity Interests
|
$36,347,315
|
$14,705,512
|
$-
|
$51,052,827
|
|
Money Market Funds
|
-
|
4,716,187
|
-
|
4,716,187
|
|
Total Investments
|
$36,347,315
|
$19,421,699
|
$-
|
$55,769,014
|
|
Invesco Nasdaq Biotechnology ETF
|
|
|
|
|
|
Investments in Securities
|
|
|
|
|
|
Common Stocks & Other Equity Interests
|
$67,285,607
|
$-
|
$359
|
$67,285,966
|
|
Money Market Funds
|
5,398
|
13,261,010
|
-
|
13,266,408
|
|
Total Investments
|
$67,291,005
|
$13,261,010
|
$359
|
$80,552,374
|
|
Invesco Nasdaq Free Cash Flow Achievers ETF
|
|
|
|
|
|
Investments in Securities
|
|
|
|
|
|
Common Stocks & Other Equity Interests
|
$11,831,172
|
$-
|
$-
|
$11,831,172
|
|
Money Market Funds
|
-
|
189,266
|
-
|
189,266
|
|
Total Investments
|
$11,831,172
|
$189,266
|
$-
|
$12,020,438
|
|
Invesco PHLX Semiconductor ETF
|
|
|
|
|
|
Investments in Securities
|
|
|
|
|
|
Common Stocks & Other Equity Interests
|
$2,428,523,725
|
$-
|
$-
|
$2,428,523,725
|
|
Money Market Funds
|
979,209
|
21,477,305
|
-
|
22,456,514
|
|
Total Investments
|
$2,429,502,934
|
$21,477,305
|
$-
|
$2,450,980,239
|
|
Invesco Solar ETF
|
|
|
|
|
|
Investments in Securities
|
|
|
|
|
|
Common Stocks & Other Equity Interests
|
$1,338,692,206
|
$954,077,825
|
$-
|
$2,292,770,031
|
|
Money Market Funds
|
872,051
|
504,528,168
|
-
|
505,400,219
|
|
Total Investments
|
$1,339,564,257
|
$1,458,605,993
|
$-
|
$2,798,170,250
|